Home » Healthcare » Pharmaceuticals » United States Gastrointestinal Products Market

United States Gastrointestinal Products Market By Devices (Endoscopy Devices, Ablation Devices, Motility Testing Devices, Biopsy Devices, Stenting Devices); By Indications (Gastrointestinal Cancers, Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, Inflammatory Bowel Disease, Other Diseases); By End-User (Hospitals, Ambulatory Surgical Centers & Independent Surgical Centers, Clinics, Other End Users) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
United States Gastrointestinal Products Market Size 2023	USD 4,030.73 million
United States Gastrointestinal Products Market, CAGR	6.20%
United States Gastrointestinal Products Market Size 2032	USD 6,927.35 million

Market Overview

The United States Gastrointestinal Products Market is projected to grow from USD 4,030.73 million in 2023 to USD 6,927.35 million by 2032, registering a CAGR of 6.20% during the forecast period.

The United States gastrointestinal products market is driven by the increasing prevalence of gastrointestinal disorders, including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), which necessitates effective treatment solutions. Rising awareness regarding digestive health, coupled with advancements in pharmaceutical formulations and delivery systems, further fuels market growth. An aging population and changing dietary habits have heightened the demand for gastrointestinal products, while increased healthcare spending supports improved access to treatments. Additionally, the integration of advanced technologies, such as precision medicine and targeted drug therapies, has enhanced the efficacy and safety of these products. Emerging trends include the growing adoption of over-the-counter (OTC) gastrointestinal products for self-care and the expansion of probiotic-based solutions to promote gut health. As key players invest in research and development, innovative product launches continue to shape the competitive landscape, contributing to the sustained growth of this market.

The United States gastrointestinal products market is influenced by regional factors such as healthcare infrastructure, patient demographics, and prevalence of gastrointestinal disorders. Key players in the market include major companies like Olympus, Boston Scientific, Fujifilm, Medtronic, and Stryker, which provide a wide range of diagnostic and therapeutic devices. These companies are at the forefront of innovation, offering advanced endoscopy devices, ablation tools, and motility testing systems to address the growing demand for gastrointestinal treatments. The competitive landscape is further shaped by Ethicon Endo-Surgery, Smith & Nephew, and Karl Storz, which contribute significantly through their specialized products for gastrointestinal surgeries and diagnostics. As demand for advanced and minimally invasive treatments increases, these key players are expanding their portfolios and focusing on research and development to maintain leadership in this evolving market.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The United States gastrointestinal products market is valued at USD 4,030.73 million in 2023 and is expected to reach USD 6,927.35 million by 2032, growing at a CAGR of 6.20%.
Increasing prevalence of gastrointestinal disorders such as IBS, IBD, and gastrointestinal cancers is driving demand for advanced diagnostic and therapeutic devices.
The adoption of probiotic-based solutions and the rise in digital health technologies are emerging trends in the market.
Biologics and targeted therapies for complex gastrointestinal disorders are gaining popularity due to their improved efficacy and safety profiles.
High treatment costs and regulatory challenges related to product approvals and safety concerns are major market restraints.
The Western United States leads the market, supported by advanced healthcare systems and a high prevalence of gastrointestinal conditions.
Key players such as Olympus, Boston Scientific, Medtronic, and Stryker are investing in R&D to enhance their product offerings and expand market share.

Market Drivers

Increasing Prevalence of Gastrointestinal Disorders

The rising incidence of gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), significantly drives the United States gastrointestinal products market. These conditions, attributed to factors like poor dietary habits, stress, and sedentary lifestyles, require effective treatment and management solutions. For instance, according to the Crohn’s & Colitis Foundation, over 1.6 million Americans live with IBD, highlighting the demand for specialized gastrointestinal therapies. This growing patient base underpins the market’s expansion, fostering advancements in drug formulations and treatment strategies.

Advancements in Pharmaceutical Technologies

Innovations in pharmaceutical technologies play a pivotal role in boosting the gastrointestinal products market. The development of targeted drug delivery systems, biologics, and biosimilars enhances the efficacy and safety of treatments for GI disorders. Precision medicine, focusing on tailored therapies based on individual genetic profiles, has emerged as a transformative trend, offering personalized solutions for complex conditions. These advancements improve patient outcomes and broaden the scope for market players to introduce innovative products, driving market growth.

Aging Population and Changing Lifestyle Patterns

An aging population in the United States contributes to the rising demand for gastrointestinal products, as older adults are more prone to GI issues due to physiological changes and comorbidities. Additionally, shifts in lifestyle patterns, such as increased consumption of processed foods and reduced physical activity, exacerbate digestive problems across age groups. For instance, according to the U.S. Census Bureau, the population aged 65 and over grew by 38.6% from 2010 to 2020. This demographic and lifestyle-driven surge in gastrointestinal disorders has created opportunities for pharmaceutical companies to expand their product portfolios and cater to diverse patient needs.

Growing Preference for Over-the-Counter (OTC) Products

The increasing availability and acceptance of OTC gastrointestinal products have further propelled market growth. Consumers are increasingly adopting self-care approaches to address minor GI issues, such as acidity and indigestion, reducing the burden on healthcare systems. The wide range of OTC offerings, including antacids, laxatives, and probiotics, provides convenience and affordability, driving consumer demand. This trend, supported by aggressive marketing strategies from key players, has expanded the reach of gastrointestinal products to a broader audience.

Market Trends

Rising Adoption of Probiotic-Based Solutions

The growing focus on gut health has significantly increased the adoption of probiotic-based gastrointestinal products in the United States. Probiotics, known for their ability to restore and maintain gut microbiota balance, have gained popularity among consumers seeking preventive and natural solutions for digestive issues. This trend is further bolstered by scientific evidence supporting the efficacy of probiotics in managing conditions like irritable bowel syndrome (IBS) and diarrhea. As awareness of the benefits of probiotics expands, pharmaceutical and nutraceutical companies are innovating and launching new probiotic formulations to capture market share.

Surge in Biologics and Targeted Therapies

Biologics and targeted therapies are transforming the treatment landscape for complex gastrointestinal disorders such as Crohn’s disease and ulcerative colitis. These advanced therapies offer improved efficacy and fewer side effects compared to traditional medications, making them a preferred choice among healthcare providers and patients. For example, the FDA has approved several biologics specifically for the treatment of Crohn’s disease and ulcerative colitis. The continued development of biosimilars has also enhanced market accessibility by offering cost-effective alternatives to branded biologics. As pharmaceutical companies invest heavily in R&D to expand their biologics portfolio, these products are poised to play a pivotal role in driving market growth.

Integration of Digital Health Technologies

Digital health technologies are increasingly being integrated into gastrointestinal product offerings, enabling better disease management and patient monitoring. Mobile health apps, wearable devices, and telemedicine platforms allow patients to track symptoms, adhere to treatment regimens, and communicate with healthcare providers remotely. These advancements not only improve patient outcomes but also encourage proactive disease management. Pharmaceutical companies are collaborating with tech firms to develop digital therapeutics tailored for GI disorders, underscoring the convergence of healthcare and technology in the market.

Expansion of Over-the-Counter (OTC) Product Portfolios

Key market players are expanding their OTC gastrointestinal product portfolios to meet the growing demand for self-care solutions. Consumers are increasingly opting for OTC options to manage common digestive issues like heartburn, indigestion, and constipation. This trend is driven by the convenience, affordability, and widespread availability of OTC products. Aggressive marketing strategies and consumer education campaigns have further fueled the adoption of these solutions, creating a competitive and dynamic OTC segment within the gastrointestinal products market

Market Challenges Analysis

High Costs and Limited Accessibility of Advanced Therapies

One of the key challenges in the United States gastrointestinal products market is the high cost of advanced therapies, such as biologics and targeted treatments, which limits accessibility for many patients. While these therapies offer significant advantages in managing severe gastrointestinal disorders like Crohn’s disease and ulcerative colitis, their premium pricing poses a financial burden on patients and healthcare systems. For instance, the cost per remission for advanced therapies can be as high as $787,998. Even with insurance coverage, out-of-pocket expenses can remain substantial, deterring widespread adoption. Furthermore, disparities in healthcare access across different regions exacerbate the issue, leaving some populations underserved and unable to benefit from cutting-edge treatments.

Regulatory Hurdles and Safety Concerns

Stringent regulatory requirements and safety concerns also present significant challenges for market growth. The development and approval process for new gastrointestinal drugs and therapies is complex and time-intensive, often involving high costs and uncertainty. Ensuring compliance with FDA standards while addressing potential side effects and long-term safety concerns can delay product launches and increase development expenses. Additionally, the recall of gastrointestinal products due to adverse events or manufacturing issues can damage brand reputation and erode consumer trust, further hindering market expansion. These regulatory and safety challenges compel companies to adopt rigorous testing and quality assurance measures, which may slow innovation and increase operational costs.

Market Opportunities

Expanding Demand for Personalized Medicine

The United States gastrointestinal products market presents significant opportunities in the growing field of personalized medicine. Advances in genetic research and precision diagnostics have paved the way for tailored treatments that address the specific needs of individual patients. Personalized approaches, such as biomarker-driven therapies, are particularly valuable in managing complex gastrointestinal disorders like Crohn’s disease and ulcerative colitis. Pharmaceutical companies investing in genomic studies and companion diagnostics can gain a competitive edge by offering innovative, patient-centric solutions. This trend aligns with the increasing emphasis on precision medicine in healthcare, fostering the development of targeted therapies with improved efficacy and reduced side effects.

Growth Potential in Probiotic and Natural Solutions

The rising consumer preference for natural and preventive health solutions presents another lucrative opportunity in the gastrointestinal products market. Probiotic-based products, known for promoting gut health and preventing digestive disorders, have witnessed increasing adoption across the United States. The demand for plant-based and organic gastrointestinal remedies is also growing as consumers seek sustainable and side-effect-free alternatives. Companies focusing on expanding their portfolios to include natural and probiotic-based products can capitalize on this trend. Additionally, the integration of functional foods and beverages enriched with digestive health benefits into daily diets offers a new avenue for market growth. By leveraging these opportunities, industry players can meet the evolving needs of health-conscious consumers while driving market expansion.

Market Segmentation Analysis:

By Devices:

The United States gastrointestinal products market is segmented by devices, which play a critical role in diagnosing and treating various GI disorders. Endoscopy devices are widely used for visualizing the gastrointestinal tract, aiding in the detection of cancers, ulcers, and other abnormalities. Ablation devices, commonly used for treating gastrointestinal cancers, utilize high-energy treatments to remove or destroy tumors, contributing to enhanced treatment options. Motility testing devices assess the function of the gastrointestinal muscles, crucial for diagnosing disorders like irritable bowel syndrome (IBS) and gastroparesis. Biopsy devices, integral in obtaining tissue samples, allow for precise diagnosis and are frequently used in cancer detection. Finally, stenting devices are used to treat obstructions in the digestive tract, often caused by cancer or other conditions. These device categories are growing as advancements in minimally invasive technologies improve patient outcomes, driving demand across multiple indications.

By Indications:

The gastrointestinal products market is also segmented by indications, which include a wide range of GI disorders. Gastrointestinal cancers, such as colorectal and esophageal cancer, require advanced diagnostic tools and therapies, contributing to the demand for endoscopy, biopsy, and ablation devices. Gastroesophageal reflux disease (GERD) affects a large portion of the population and drives demand for treatments and devices to manage reflux and prevent esophageal damage. Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, require ongoing management through both pharmaceuticals and diagnostic devices like motility testing and endoscopy. The other diseases segment includes a variety of gastrointestinal conditions that may not fit within the broader categories but still demand specialized treatments and diagnostic devices. As the prevalence of these disorders rises, the market for related devices and treatments continues to expand.

Segments:

Based on Devices:

Endoscopy Devices
Ablation Devices
Motility Testing Devices
Biopsy Devices
Stenting Devices

Based on Indications:

Gastrointestinal Cancers
Gastroesophageal Reflux Disease
Irritable Bowel Syndrome
Inflammatory Bowel Disease
Other Diseases

Based on End-User:

Hospitals
Ambulatory Surgical Centers & Independent Surgical Centers
Clinics
Other End Users

Based on the Geography:

Western United States
Midwestern United States
Southern United States
Northeastern United States

Regional Analysis

Western United States

The Western United States leads the market, holding a considerable share due to its advanced healthcare infrastructure, higher concentration of healthcare providers, and a growing number of healthcare innovations in cities like San Francisco and Los Angeles. This region is particularly strong in terms of research and development, which drives the demand for advanced gastrointestinal devices and treatments. With a market share of approximately 30%, the Western United States is expected to continue its dominance, fueled by a high prevalence of gastrointestinal disorders and the adoption of cutting-edge medical technologies.

Midwestern United States

The Midwestern United States holds a significant portion of the gastrointestinal products market, contributing around 25% to the overall market share. This region’s strong healthcare system, alongside a rising awareness of gastrointestinal health, drives the demand for diagnostic and therapeutic devices. The Midwestern states, including Illinois and Michigan, are home to several large healthcare facilities and research institutions, which further bolsters the regional market. The aging population in the Midwest also increases the incidence of gastrointestinal disorders, further propelling demand for products addressing conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastrointestinal cancers.

Southern United States

The Southern United States, comprising states like Texas, Florida, and Georgia, holds a market share of approximately 20%. The region has seen significant population growth, resulting in a larger patient base and a corresponding increase in demand for gastrointestinal products. Additionally, the South benefits from a mix of urban and rural healthcare facilities, making gastrointestinal treatments and devices accessible to diverse demographic groups. The region also faces higher rates of certain gastrointestinal conditions, such as gastroesophageal reflux disease (GERD) and obesity-related gastrointestinal disorders, creating substantial opportunities for market expansion. Healthcare improvements and state-level health programs further contribute to the region’s steady growth in the gastrointestinal products sector.

Northeastern United States

The Northeastern United States rounds out the market with a share of approximately 25%. This region is home to major healthcare hubs such as New York, Boston, and Philadelphia, where world-renowned hospitals and research institutions drive the adoption of the latest gastrointestinal treatments and diagnostic devices. The high prevalence of gastrointestinal cancers, as well as chronic conditions like IBS and IBD, in the Northeast fuels the demand for specialized medical technologies. Moreover, the growing focus on healthcare quality and the expansion of telemedicine and digital health solutions in this region also contribute to the overall market growth. As the region continues to invest in advanced medical technologies, it is poised to maintain a substantial share of the U.S. gastrointestinal products market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Olympus
Boston Scientific
Fujifilm
Ethicon Endo-Surgery
Medtronic
Stryker
Smith & Nephew
Karl Storz
Hoya
Company 10
Company 11
Company 12
Company 13
Company 14

Competitive Analysis

The United States gastrointestinal products market is highly competitive, with leading players such as Olympus, Boston Scientific, Fujifilm, Medtronic, Stryker, Ethicon Endo-Surgery, Smith & Nephew, Karl Storz, and Hoya driving innovation and growth. Leading players leverage their expertise in endoscopy, biopsy, ablation, and stenting devices to address a wide range of gastrointestinal disorders, such as gastrointestinal cancers, IBS, and IBD. For instance, the adoption of minimally invasive technologies in the U.S. has significantly improved patient outcomes and reduced recovery times. Companies are continually investing in research and development to introduce innovative products that are minimally invasive, cost-effective, and improve patient outcomes. The market is characterized by intense competition, with companies striving to differentiate themselves through product innovation, quality, and advanced features. Strategic collaborations and partnerships with healthcare providers are also common, enabling companies to enhance their product offerings and gain a competitive edge. Moreover, the shift toward personalized medicine, digital health integration, and the increasing adoption of biologics are reshaping the competitive landscape. Despite the dominance of established players, the market remains open to new entrants, especially those focused on emerging technologies and tailored solutions. The ongoing trend toward better patient care and improving healthcare delivery systems is driving competition, providing significant opportunities for both existing and new companies to expand their market presence.

Recent Developments

In April 2023, Boston Scientific announced the launch of the EXALT Model B Single-use Bronchoscope, which expands its single-use endoscopy portfolio. This device is designed for diagnostic and therapeutic bronchoscopy procedures and offers high-resolution imaging and precise control.
In March 2023, Polifarma Spa expanded its gastrointestinal portfolio through a long-term distribution agreement with Devintec Pharma Sagl, a Lugano-based company known for pioneering substance-based medical devices and the Gelsectan brand.
In April 2023, Italian pharmaceutical innovator Azienda Farmaceutica Italiana partnered with TannerLAC, Inc. to distribute Hepilor, a medical device designed to protect the digestive system mucosa, throughout Latin America.
In May 2022, Dr. Reddy’s Laboratories Ltd. announced a partnership with South Korea’s HK inno.N Corporation to supply and commercialize HK inno.N’s patented novel molecule, Tegoprazan, for treating gastrointestinal diseases in India and six key emerging markets.
In March 2022, AbbVie Inc. received U.S. FDA approval for its novel drug, RINVOQ (upadacitinib), for the treatment of moderately to severely active ulcerative colitis.

Market Concentration & Characteristics

The market concentration of gastrointestinal products in the United States is moderate, with a mix of established global players and emerging companies competing for market share. A few dominant companies control a significant portion of the market, particularly in the fields of endoscopy, biopsy devices, and ablation systems. These leaders invest heavily in research and development, driving technological innovation and offering advanced, minimally invasive solutions to address a wide range of gastrointestinal disorders. However, the presence of smaller, specialized companies focusing on niche segments, such as probiotics, functional foods, and natural treatment options, adds diversity to the market. The characteristics of the market are driven by the increasing prevalence of gastrointestinal conditions, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and gastrointestinal cancers. This demand for advanced treatment options has led to the growth of both diagnostic and therapeutic products. Furthermore, as the healthcare industry shifts toward personalized medicine and digital health, companies are integrating these technologies into their gastrointestinal products. The market is also characterized by stringent regulatory requirements, which ensure high safety and quality standards but can slow the pace of product development. Despite this, the ongoing need for innovation, coupled with the aging population and increasing health awareness, presents continuous growth opportunities for companies operating within the gastrointestinal product sector.

Report Coverage

The research report offers an in-depth analysis based on Devices, Indications, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The United States gastrointestinal products market is expected to continue its growth, driven by an increasing prevalence of gastrointestinal disorders.
Technological advancements in endoscopy and minimally invasive procedures will shape the future of gastrointestinal treatments.
The demand for personalized medicine and targeted therapies will drive the development of more precise gastrointestinal products.
The rise in health-conscious consumers will fuel the demand for natural and probiotic-based gastrointestinal solutions.
Increased focus on early diagnosis and preventive care will lead to higher adoption of diagnostic devices like endoscopes and biopsy tools.
Digital health technologies and telemedicine will become more integrated into gastrointestinal care, improving patient monitoring and outcomes.
Biologic treatments for conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) will gain popularity.
The aging population will continue to be a major driver, with older individuals being more prone to gastrointestinal issues.
Competitive pressures will push companies to innovate, leading to the introduction of cost-effective and more efficient products.
Regulatory advancements and collaborations between companies and healthcare providers will contribute to faster product development and market entry.

CHAPTER NO. 1 : INTRODUCTION 20

1.1.1. Report Description 20

Purpose of the Report 20

USP & Key Offerings 20

1.1.2. Key Benefits for Stakeholders 20

1.1.3. Target Audience 21

1.1.4. Report Scope 21

CHAPTER NO. 2 : EXECUTIVE SUMMARY 22

2.1. GASTROINTESTINAL PRODUCTS Market Snapshot 22

2.1.1. United States GASTROINTESTINAL PRODUCTS Market, 2018 – 2032 (USD Million) 23

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 24

3.1. Russia-Ukraine and Israel-Palestine War Impacts 24

CHAPTER NO. 4 : GASTROINTESTINAL PRODUCTS MARKET – INDUSTRY ANALYSIS 25

4.1. Introduction 25

4.2. Market Drivers 26

4.2.1. GI Disorders on a Rise 26

4.2.2. New and innovative technologies driving the market 27

4.3. Market Restraints 28

4.3.1. Stringent Regulations 28

4.4. Market Opportunities 29

4.4.1. Market Opportunity Analysis 29

4.5. Porter’s Five Forces Analysis 30

4.6. Value Chain Analysis 31

4.7. Buying Criteria 32

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 33

5.1. Import Analysis by United States 33

5.1.1. United States GASTROINTESTINAL PRODUCTS Market Import Volume/Revenue, By United States, 2018 – 2023 33

5.2. Export Analysis by United States 34

5.2.1. United States GASTROINTESTINAL PRODUCTS Market Export Volume/Revenue, By United States, 2018 – 2023 34

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 35

6.1. Demand Analysis by United States 35

6.1.1. United States GASTROINTESTINAL PRODUCTS Market Demand Volume/Revenue, By United States, 2018 – 2023 35

6.2. Supply Analysis by United States 36

6.2.1. United States GASTROINTESTINAL PRODUCTS Market Supply Volume/Revenue, By United States, 2018 – 2023 36

CHAPTER NO. 7 : PRODUCTION ANALYSIS 37

7.1. Production Analysis by United States 37

7.1.1. United States GASTROINTESTINAL PRODUCTS Market Production Volume/Revenue, By United States, 2018 – 2023 37

CHAPTER NO. 8 : PRICE ANALYSIS 38

8.1. Price Analysis by Devices 38

8.1.1. United States GASTROINTESTINAL PRODUCTS Market Price, By Devices, 2018 – 2023 38

8.1.2. United States Devices Market Price, By Devices, 2018 – 2023 38

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 39

9.1. Key Raw Materials and Suppliers 39

9.2. Key Raw Materials Price Trend 39

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 40

10.1. Manufacturing Cost Analysis 40

10.2. Manufacturing Process 40

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 41

11.1. Company Market Share Analysis – 2023 41

11.1.1. United States GASTROINTESTINAL PRODUCTS Market: Company Market Share, by Volume, 2023 41

11.1.2. United States GASTROINTESTINAL PRODUCTS Market: Company Market Share, by Revenue, 2023 42

11.1.3. United States GASTROINTESTINAL PRODUCTS Market: Top 6 Company Market Share, by Revenue, 2023 42

11.1.4. United States GASTROINTESTINAL PRODUCTS Market: Top 3 Company Market Share, by Revenue, 2023 43

11.2. United States GASTROINTESTINAL PRODUCTS Market Company Volume Market Share, 2023 44

11.3. United States GASTROINTESTINAL PRODUCTS Market Company Revenue Market Share, 2023 45

11.4. Company Assessment Metrics, 2023 46

11.4.1. Stars 46

11.4.2. Emerging Leaders 46

11.4.3. Pervasive Players 46

11.4.4. Participants 46

11.5. Start-ups /SMEs Assessment Metrics, 2023 46

11.5.1. Progressive Companies 46

11.5.2. Responsive Companies 46

11.5.3. Dynamic Companies 46

11.5.4. Starting Blocks 46

11.6. Strategic Developments 47

11.6.1. Acquisitions & Mergers 47

New Product Launch 47

United States Expansion 47

11.7. Key Players Product Matrix 48

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 49

12.1. PESTEL 49

12.1.1. Political Factors 49

12.1.2. Economic Factors 49

12.1.3. Social Factors 49

12.1.4. Technological Factors 49

12.1.5. Environmental Factors 49

12.1.6. Legal Factors 49

12.2. Adjacent Market Analysis 49

CHAPTER NO. 13 : GASTROINTESTINAL PRODUCTS MARKET – BY DEVICES SEGMENT ANALYSIS 50

13.1. GASTROINTESTINAL PRODUCTS Market Overview, by Devices Segment 50

13.1.1. GASTROINTESTINAL PRODUCTS Market Revenue Share, By Devices, 2023 & 2032 51

13.1.2. GASTROINTESTINAL PRODUCTS Market Attractiveness Analysis, By Devices 52

13.1.3. Incremental Revenue Growth Opportunity, by Devices, 2024 – 2032 52

13.1.4. GASTROINTESTINAL PRODUCTS Market Revenue, By Devices, 2018, 2023, 2027 & 2032 53

13.2. Endoscopy Devices 54

13.3. Ablation Devices 55

13.4. Motility Testing Devices 56

13.5. Biospy Devices 57

13.6. Stenting Devices 58

CHAPTER NO. 14 : GASTROINTESTINAL PRODUCTS MARKET – BY INDICATIONS SEGMENT ANALYSIS 59

14.1. GASTROINTESTINAL PRODUCTS Market Overview, by Indications Segment 59

14.1.1. GASTROINTESTINAL PRODUCTS Market Revenue Share, By Indications, 2023 & 2032 60

14.1.2. GASTROINTESTINAL PRODUCTS Market Attractiveness Analysis, By Indications 61

14.1.3. Incremental Revenue Growth Opportunity, by Indications, 2024 – 2032 61

14.1.4. GASTROINTESTINAL PRODUCTS Market Revenue, By Indications, 2018, 2023, 2027 & 2032 62

14.2. Gastrointestinal Cancers 63

14.3. Gastroesophageal Reflux Disease 64

14.4. Irritable Bowl Syndrome 65

14.5. Inflammatory Bowel Disease 66

14.6. Other Disease 67

CHAPTER NO. 15 : GASTROINTESTINAL PRODUCTS MARKET – BY END-USER SEGMENT ANALYSIS 68

15.1. GASTROINTESTINAL PRODUCTS Market Overview, by End-user Segment 68

15.1.1. GASTROINTESTINAL PRODUCTS Market Revenue Share, By End-user, 2023 & 2032 69

15.1.2. GASTROINTESTINAL PRODUCTS Market Attractiveness Analysis, By End-user 70

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 70

15.1.4. GASTROINTESTINAL PRODUCTS Market Revenue, By End-user, 2018, 2023, 2027 & 2032 71

15.2. Hospital 72

15.3. Ambulatory Surgical Center & Independent Surgical Center 73

15.4. Clinics 74

15.5. Other End Users 75

CHAPTER NO. 16 : COMPANY PROFILES 76

16.1. Olympus 76

16.1.1. Company Overview 76

16.1.2. Product Portfolio 76

16.1.3. Swot Analysis 76

16.1.4. Business Strategy 77

16.1.5. Financial Overview 77

16.2. Boston Scientific 78

16.3. Fujifilm 78

16.4. Ethicon Endo-Surgery 78

16.5. Medtronic 78

16.6. Stryker 78

16.7. Smith & Nephew 78

16.8. Karl Storz 78

16.9. Hoya 78

16.10. Company 10 78

16.11. Company 11 78

16.12. Company 12 78

16.13. Company 13 78

16.14. Company 14 78

List of Figures

FIG NO. 1. United States GASTROINTESTINAL PRODUCTS Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for United States GASTROINTESTINAL PRODUCTS Market 29

FIG NO. 3. Value Chain Analysis for United States GASTROINTESTINAL PRODUCTS Market 30

FIG NO. 4. United States GASTROINTESTINAL PRODUCTS Market Import Volume/Revenue, By United States, 2018 – 2023 32

FIG NO. 5. United States GASTROINTESTINAL PRODUCTS Market Export Volume/Revenue, By United States, 2018 – 2023 33

FIG NO. 6. United States GASTROINTESTINAL PRODUCTS Market Demand Volume/Revenue, By United States, 2018 – 2023 34

FIG NO. 7. United States GASTROINTESTINAL PRODUCTS Market Supply Volume/Revenue, By United States, 2018 – 2023 35

FIG NO. 8. United States GASTROINTESTINAL PRODUCTS Market Production Volume/Revenue, By United States, 2018 – 2023 36

FIG NO. 9. United States GASTROINTESTINAL PRODUCTS Market Price, By Devices, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. GASTROINTESTINAL PRODUCTS Market – Company Volume Market Share, 2023 43

FIG NO. 18. GASTROINTESTINAL PRODUCTS Market – Company Revenue Market Share, 2023 44

FIG NO. 19. GASTROINTESTINAL PRODUCTS Market Revenue Share, By Devices, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Devices 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Devices, 2024 – 2032 51

FIG NO. 22. GASTROINTESTINAL PRODUCTS Market Revenue, By Devices, 2018, 2023, 2027 & 2032 52

FIG NO. 23. United States GASTROINTESTINAL PRODUCTS Market for Endoscopy Devices, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. United States GASTROINTESTINAL PRODUCTS Market for Ablation Devices, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. United States GASTROINTESTINAL PRODUCTS Market for Motility Testing Devices, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. United States GASTROINTESTINAL PRODUCTS Market for Biospy Devices, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. United States GASTROINTESTINAL PRODUCTS Market for Stenting Devices, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. GASTROINTESTINAL PRODUCTS Market Revenue Share, By Indications, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Indications 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Indications, 2024 – 2032 60

FIG NO. 31. GASTROINTESTINAL PRODUCTS Market Revenue, By Indications, 2018, 2023, 2027 & 2032 61

FIG NO. 32. United States GASTROINTESTINAL PRODUCTS Market for Gastrointestinal Cancers, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. United States GASTROINTESTINAL PRODUCTS Market for Gastroesophageal Reflux Disease, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. United States GASTROINTESTINAL PRODUCTS Market for Irritable Bowl Syndrome, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. United States GASTROINTESTINAL PRODUCTS Market for Inflammatory Bowel Disease, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. United States GASTROINTESTINAL PRODUCTS Market for Other Disease, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. GASTROINTESTINAL PRODUCTS Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. GASTROINTESTINAL PRODUCTS Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. United States GASTROINTESTINAL PRODUCTS Market for Hospital, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. United States GASTROINTESTINAL PRODUCTS Market for Ambulatory Surgical Center & Independent Surgical Center, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. United States GASTROINTESTINAL PRODUCTS Market for Clinics, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. United States GASTROINTESTINAL PRODUCTS Market for Other End Users, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. United States GASTROINTESTINAL PRODUCTS Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. GASTROINTESTINAL PRODUCTS Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. GASTROINTESTINAL PRODUCTS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. United States GASTROINTESTINAL PRODUCTS Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. United States GASTROINTESTINAL PRODUCTS Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. United States GASTROINTESTINAL PRODUCTS Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. GASTROINTESTINAL PRODUCTS Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. GASTROINTESTINAL PRODUCTS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. United States GASTROINTESTINAL PRODUCTS Market for Distribution Channel 1, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. United States GASTROINTESTINAL PRODUCTS Market for Distribution Channel 2, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. United States GASTROINTESTINAL PRODUCTS Market for Distribution Channel 3, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. United States GASTROINTESTINAL PRODUCTS Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. United States GASTROINTESTINAL PRODUCTS Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : United States GASTROINTESTINAL PRODUCTS Market: Snapshot 18

TABLE NO. 2. : Drivers for the GASTROINTESTINAL PRODUCTS Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the GASTROINTESTINAL PRODUCTS Market: Impact Analysis 24

TABLE NO. 4. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Devices, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Devices, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Devices, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Indications, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Indications, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : United States GASTROINTESTINAL PRODUCTS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the United States Gastrointestinal Products market?

The United States gastrointestinal products market is valued at USD 4,030.73 million in 2023 and is projected to grow to USD 6,927.35 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.20%.

What factors are driving the growth of the United States Gastrointestinal Products market?

The market growth is driven by the rising prevalence of gastrointestinal disorders like IBS, IBD, and GERD, advancements in pharmaceutical technologies, an aging population, changing lifestyle patterns, and increasing consumer preference for over-the-counter (OTC) solutions. The integration of precision medicine and targeted therapies further supports market expansion

What are the key segments within the United States Gastrointestinal Products market?

The key segments include:
• By Devices: Endoscopy devices, ablation devices, motility testing devices, biopsy devices, and stenting devices.
• By Indications: Gastrointestinal cancers, GERD, IBS, IBD, and other diseases.
• By End-User: Hospitals, ambulatory surgical centers, clinics, and other end users.
• By Geography: Regions such as Western United States, Midwestern United States, Southern United States, and Northeastern United States.

Who are the major players in the United States Gastrointestinal Products market?

Key players include Olympus, Boston Scientific, Fujifilm, Medtronic, Stryker, Ethicon Endo-Surgery, Smith & Nephew, and Karl Storz. These companies lead the market through innovative product offerings, extensive portfolios, and strategic investments in research and development.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –